Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature
- Focus Registrational; Therapeutic Use
- Sponsors Dong-A Pharmaceutical
- 28 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Dec 2013 New trial record